Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Selling timed perfectly with a broker recommendation and a $2 price target ??
Or all a big simple coincidence ??
https://finance.yahoo.com/screener/insider/JAVITT%20DANIEL%20C
panton, thanks for consistently keeping us updated with developments and news.
This hopefully is especially promising with tremendous potential.
A link to your news......
https://www.marketscreener.com/quote/stock/RELIEF-THERAPEUTICS-HOLDI-5527488/news/Relief-Therapeutics-Announces-Promising-Initial-Stability-Data-on-a-New-Formulation-of-RLF-100-R-41176782/
Looks like its Time for approval of aviptadil....
https://rumble.com/search/video?q=Dr%20Robert
https://rumble.com/search/video?q=Dr%20Peter
https://rumble.com/search/video?q=vaccine%20injuries
https://rumble.com/v1817sw-covid-vaccine-injuries-overwhelm-courts.html
https://rumble.com/search/video?q=vaccine%20deaths
https://rumble.com/search/video?q=Front%20Line%20Doctors
Looks like its Time for approval of aviptadil.... WHY NOT ?
And they are giving this to small children and infants, not to mention
pregnant women along with perfectly healthy citizens.
https://citizenfreepress.com/breaking/the-vaccine-will-eventually-be-known-as-biggest-scandal-in-medical-history/
How about approval of a safe effective med like RLF Aviptadil. ????
https://thelibertydaily.com/flip-flopping-fascist-fear-fuhrer-fauci-admits-he-lied-about-covid-natural-immunity/
Not lookin good for Neuro or .....a guy that is a "consultant" , .....
Time to settle with RLF and pronto ?
https://ir.stockpr.com/neurorxpharma/sec-filings-email/content/0000950142-22-002222/eh220269223_8k.htm
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On July 12, 2022, the Company received a written notification (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Registrant was not in compliance with Nasdaq Listing Rule 5450(a)(1), as the Registrant’s closing bid price for its common stock was below $1.00 per share for the last thirty (30) consecutive business days.
FOUR CLOT SHOTS and still going.....yep.....safe, effective, & free
we were told by the gobrmint that spent one billion tax $$$ telling us so. .
https://citizenfreepress.com/breaking/biden-infected-with-covid/
Maybe time for another booster shot, eh Jose ?
Or approval of RLF that is safe and effective.
From Guiseppe 5 hours ago on another b board.....
at you who
https://www.researchgate.net/publication/361024336_European_Journal_of_Pharmaceutical_and_Medical_Research_243_AVIPTADIL_IN_ACUTE_RESPIRATORY_DISTRESS_SYNDROME_ASSOCIATED_WITH_COVID-19_INFECTION_SJIF_Impact_Factor_6222_EUROPEAN_JOURNAL_OF_PHARMACEUTIC
Conclusion: Use of Aviptadil was safe and effective in improving the
resolution of respiratory failure, shortening the time to recovery, decreasing respiratory distress and preventing
death in respiratory failure patients. The rapidity and magnitude of clinical effect suggests a highly specific role of
Aviptadil in combating the lethal effects of Acute Respiratory Distress Syndrome associated with COVID-19.
Another New CEO for Neuro Installed !!!
Call me skeptical at best.
A desperate attempt to re float a sinking ship ??
https://finance.yahoo.com/news/nrx-pharmaceuticals-announces-appointment-stephen-111500208.html
NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director
Wed, July 13, 2022 at 6:15 AM
In this article:
NRXP
-8.72%
NRXPW
-3.85%
Extensive experience in Law, Finance, and Management of Public and Private Biotechnology Companies
Proven track record of creating value for shareholders
National Science Board Presidential Appointee, 2018-2024
Former roles at Federal Deposit Insurance Corporation (FDIC) and E*Trade Financial
RADNOR, Pa., July 13, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP): ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, today announced the appointment of Stephen Willard, as its Chief Executive Officer ("CEO") and a member of the Company's Board of Directors. The Company's interim CEO, Robert Besthof, will continue to support the Company and return to his roles as Head of Operations and Chief Commercial Officer.
Stephen Willard, Chief Executive Officer, Director, NRx Pharmaceuticals, Inc.
Stephen Willard, Chief Executive Officer, Director, NRx Pharmaceuticals, Inc.
@NRXP Board Appoints BioPharma Veteran and National Science Board Presidential Appointee to Lead NRx Pharmaceuticals, Inc.
"We are delighted to have attracted a candidate like Steve whose background and experience align with NRx Pharmaceuticals' current needs. Steve's passion to provide breakthrough therapies to address critical unmet needs positions the Company for success," said Patrick Flynn, a member of the Company's Board of Directors. "We look forward to Steve's leadership of the Company in the next stages of growth to benefit patients, our shareholders, and the broader NRx team."
Mr. Willard brings a wealth of experience in the management of publicly traded biotechnology companies, together with his background in law and finance. Most recently, Mr. Willard served as CEO of Cellphire Therapeutics, where he grew the company and shepherded their revolutionary human platelet platform through key clinical trials, growing the company and significantly increasing the share price. Prior to Cellphire, he served as CEO of publicly traded Flamel Technologies now known as Avadel Pharmaceuticals. Mr. Willard is currently serving a six-year term from 2018-2024 as a presidential appointee to the National Science Board.
Mr. Willard's career in financial services includes government service as Associate Director of the Federal Deposit Insurance Corporation (FDIC), where he served in the United States Senior Executive Service (SES) from 1991-1994, and on the board of E*Trade Financial Services from 2000-2014. He has practiced law in New York, London, and Washington, D.C. Mr. Willard earned his undergraduate degree from Williams College and attended Yale University where he earned a JD in law.
PW.....Its my hope that RLF will possibly be in a position to force favorable control of Neuro in one way or another, and have the NRX-101 BTD compound for Bipolar Depression at a bargain price. ( assuming its not another bogus NRX product and the class action can not attach assets under development )
Seems thats about all Neuro has left, except massive liabilities.
Failed mediation..... .. Courtesy of poster on another board... ....y who ?
From....
dnctrk 20 hours ago
The judge approves…
https://iapps.courts.state.ny.us/nyscef/ViewDocument?docIndex=IM0RLpwBQajIfItvpr_PLUS_3tA==
From....
Wong 20 hours ago
Pressure is on NRXP. Is this why JJ's brother just donated 2 million shares to his personal foundation? Executives usually do this before a steep drop in the SP. NRXP has shown itself to be very "clairvoyant" in the past.
https://www.relieftherapeutics.com/newsblog-detail/?newsID=2293059
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Relief Therapeutics Holding SA / Key word(s): Miscellaneous
04-Jul-2022 / 07:15 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Geneva, Switzerland, July 4, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), announced today that it has filed Amendment No. 4 to its Registration Statement on Form 20-F ("Registration Statement") with the U.S. Securities and Exchange Commission ("SEC"). The Registration Statement is intended to register Relief as a reporting company under the Securities Exchange Act of 1934. The Registration Statement has been filed as part of an ongoing program to convert Relief's Level 1 American Depositary Receipt ("ADR") program in the United States to a Level 2 ADR program, and is part of Relief's ongoing efforts to list its ADRs on the NASDAQ Stock Market. The NASDAQ listing will only occur after the Registration Statement has become effective, which is subject to a continuing review of the Registration Statement by the SEC, and the filing by Relief of a listing application with the NASDAQ (which has not yet occurred).
Yes, PW, and plenty of other areas that could use some development.
And why not use a BP partner to move these other programs forward ??
PW...Ok...."CYNICAL" that sounds reasonable, all things considered.
https://nypost.com/2022/06/29/dr-fauci-reveals-covid-rebound-after-pfizers-paxlovid-treatment/?utm_campaign=SocialFlow&utm_medium=SocialFlow&utm_source=NYPTwitter
Perhaps a third course of the ol PAX LOVE and or a 5th clot shot in the rear end, in the bone head, or even the throwing/ pitching arm....you never know what might work.. it is kind of experimental, but clearly not as advertised...(.safe, effective, free )
Wish someone at RLF would make that call and offer him some adviptadil.
Interesting how "rebound" now has a meaning of "reinfection"
..
Evidently No Aviptadil or RLF-100 for the Flip Flopper.........
............ Evidently the shots do not work as advertised, ie...safe, effective, and free
Maybe Triple Masks and or a Ventilator / Remdesvir. ???
https://abcnews.go.com/US/fauci-taking-2nd-paxlovid-experiencing-rebound-antiviral-treatment/story?id=85922417
<The Food and Drug Administration also says that “there is no evidence of benefit at this time for a longer course of treatment … or repeating a treatment course of Paxlovid in patients with recurrent COVID-19 symptoms following completion of a treatment course.”>
< Earlier this month, Pfizer also reported new clinical trial data that showed that Paxlovid did not significantly reduce the risk of going to the hospital or dying in people with standard risk of developing severe illness. However, the company said the treatment still works well in high-risk individuals.>
Sounds Confusing......One, Two, three or, four courses ????
https://finance.yahoo.com/news/acer-therapeutics-announces-initiation-pivotal-123000936.html
Acer Therapeutics Inc.
NEWTON, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the initiation of patient screening in its Phase 3 DiSCOVER (Decentralized Study of Celiprolol on vEDS-related Event Reduction) clinical trial of EDSIVO™ (celiprolol) for the treatment of patients with COL3A1-positive vascular Ehlers-Danlos Syndrome (vEDS).
“With no approved treatments available for vEDS, ongoing clinical evaluation of EDSIVO™ (celiprolol) is an important step that we hope could lead to the first available treatment option for this fatal disorder,” said Adrian Quartel, MD, FFPM, Chief Medical Officer of Acer. “The innovative, decentralized study design will allow for greater access and ease of administration for vEDS patients, mobile nurses, remote clinical research coordinators and investigators. We'd like to thank all the patients, their family members, the advocacy groups and clinicians who have expressed interest in learning more about participating in the study, and look forward to rapidly enrolling the trial.”
Evidently ...Dal Bosco vs NRXP class action lawsuit dismissed
Interesting only as a lawsuit that I had not ever even known about.
https://finance.yahoo.com/news/class-action-suit-against-nrx-223300879.html
https://www.prnewswire.com/news-releases/class-action-suit-against-nrx-pharmaceuticals-dismissed-301573556.html
EXCLUSIVE: Shocking microscopy photos of blood clots extracted from those who “suddenly died” – crystalline structures, nanowires, chalky particles and fibrous structures
https://www.naturalnews.com/2022-06-12-blood-clots-microscopy-suddenly-died.html
And our gov. spent one billion dollars advertising ' its safe efeective and free."
Get your clot shot today..........
How about RLF-100 ????????.
https://www.wnd.com/2022/06/pathologist-covid-19-shots-causing-foot-long-blood-clots/
Pathologist: COVID-19 shots causing foot-long blood clots
'Too many people are silent, and silence is compliance'
A pathologist who heads one of America's leading labs is finding unusually long blood clots, as long as one foot, in the bodies of deceased people who received COVID-19 vaccines.
Dr. Ryan Cole of Cole Diagnostics in Boise, Idaho, said his lab is "seeing mushy organs, we're seeing incredibly inflamed organs."
"We know the spike protein causes all the ... bad outcomes that the virus did in 2020," he said in an interview with Greg Hunter for USAWatchdog reported by Just the News.
Cole said that in people with comorbidities – serious chronic diseases – the synthetic spike protein in the mRNA vaccines produced by Pfizer and Moderna are "causing inflammation in the lung, the brain, the liver, the kidneys, the heart; it's causing the same damage that the virus was causing."
However, he added, "in the body, the shots are persisting and making more spike protein than if you had a natural infection."
Cole, whose laboratory receives tissue samples from morticians across the country, cited a Stanford University study published in the journal Cell that found the vaccine's spike protein remains in the body for at least eight weeks.
........The morticians, Cole said, ended up pulling out "six-inch clots, 12-inch clots, two to three-foot-long clots."
"Because, you know, from the hip down into the leg, you have a long vein called the saphenous vein. And so they were pulling long clots out of your longer veins. And ... they hadn't seen anything like this previously."
In February, as WND reported, a veteran embalmer told Kirsch he and more than a dozen colleagues in the industry had been noticing strange blood clots in most of their cases.
SO>>>> IS it About Time for a safe therapeutic like AVIPTADIL. RLF-100 , eh ?????
Relief Therapeutics Needs A Lawfirm Like This One.....
.........Boyden Gray & Associates
https://www.zerohedge.com/covid-19/doctors-suing-food-and-drug-administration-over-ivermectin
Very similar situation for RLF-100 as a safe effective med that has been previously approved for a long time.
the FDA had violated well-established law that allows doctors to prescribe an FDA-approved drug as an off-label treatment.
Ivermectin was no different, he said. It was approved by the FDA in 1966.
“Congress recognized the importance of letting doctors be doctors and expressly prohibited the FDA from interfering with the practice of medicine,” Gray said.
“That is exactly what the FDA has done time and time again throughout this pandemic, assuming authority it doesn’t have and trying to insert itself in the medical decisions of Americans everywhere.”
Evidently nothing definite, absolute, or set in stone on the dates.
https://www.fool.com/investing/stock-market/market-sectors/healthcare/pharmaceutical-stocks/pdufa-date/
Prion Disease and the old clot shot or so called vax.
https://twoplustwoequalsfournews.wordpress.com/2022/03/05/steve-kirsch-proof-covid-vaccines-cause-prion-diseases/
https://www.legitgov.org/studies-link-incurable-prion-disease-covid-19-vaccine
https://www.theepochtimes.com/studies-link-incurable-prion-disease-with-covid-19-vaccine_4511204.html
Time for some safe therapeutic drugs like RLF-100 eh ?
JJ.... how much, if any stock, do you still retain stock in neuro ??
Thanks rollup....Great Find from the results in India.
And For emphasis..........
https://storage.googleapis.com/journal-uploads/ejpmr/article_issue/1653986940.pdf
ABSTRACT
Aim: This study is aimed at evaluating efficacy and safety of Intravenous Aviptadil as an add-on to the “Standard
of Care” treatment in severe COVID-19 patients with respiratory failure. Design, Setting and Participants: A
randomized, multicentric, double-blind, placebo-controlled, comparative Phase III clinical trial was conducted at 8
geographically distributed sites across India between April 2021 to October 2021. The study enrolled 150
participants who were tested and confirmed cases of severe COVID-19 with respiratory failure and acute
respiratory distress syndrome. Interventions: 12-hour intravenous infusions of Aviptadil over 3 successive days in
ascending doses given as 0.166 mcg/kg/hr on Day 1 (equivalent to one 10 mL vial of 150 mcg), 0.332 mcg/kg/hr
on Day 2 (equivalent to two 10 mL vials of 150 mcg each) and 0.498 mcg/kg/hr on Day 3 (equivalent to three 10
mL vials of 150 mcg each). Methodology: Severe COVID-19 patients with respiratory failure were randomized in
two groups in a ratio of 1:1, to receive either Aviptadil or Placebo. Both the study drugs were given as an add-on to
the standard of care (SOC). The SOC was kept as close as possible to the COVID-19 treatment guidelines specified
by the Government of India. The study site staff, investigator and patients were masked to the treatment allocation.
The primary endpoint of the study was resolution of respiratory failure whereas the secondary endpoints were
improvement in WHO 7-point ordinal scale, improvement in PaO2:FiO2 ratio, survival of the patients and
incidences of adverse events. Results: After the completion of treatment in Aviptadil group, an improvement was
observed in the primary outcome of resolution of respiratory failure. Proportion of patients on Aviptadil
demonstrated statistically significant odds, 2.1-fold, (p=0.0410) of being free of respiratory failure (no oxygen
requirement) at Day 3 and 2.6-fold (p=0.0035) at day 7 as compared to the placebo group. An earlier resolution
from the respiratory failure, with a median duration of 7 days was noted in the Aviptadil-treated group as compared
to 14 days in the placebo group. A higher proportion of patients on Aviptadil shifted to the milder clinical state
(32.43% vs 17.80%; p=0.0410 on Day 3 and 70.27% vs 45.21%; 0.0035 on Day 7) without the requirement of
oxygen than the placebo group. A reduction of severity (based on WHO 7-point ordinal scale) in clinical status
were also observed on Day 14 (p = 0.0005 by Wilcoxon rank sum test) and Day 28 (p = 0.0009 by Wilcoxon rank
sum test). There were 68.42% Aviptadil-treated patients who showed 2 or more points improvement on the WHO
7-point ordinal scale as compared to 44.59% in the placebo group (p=0.003; Pearson chi2 test; odds ratio, 2.69;
95% CI, 1.38-5.24) on Day 7. On day 28, patients in the Aviptadil group had higher odds (1.38) of an improvement
on WHO 7-point ordinal scale as compared to placebo with SOC. Aviptadil reduced the risk of death by 20%
(relative risk 0.80; 95% CI: 0.35, 1.66) in ARDS. Patients treated with Aviptadil demonstrated significant
improvement in PaO2/FiO2 ratio vs. placebo from day 2 to over the week (p<0.05) and beyond. There were 15
deaths in the Aviptadil group and 18 deaths in the placebo group. No deaths were attributed to the Investigational
products. COVID-19–related mortality occurred in 22% patients of the study population, due to respiratory failure
caused by underlying medical conditions. Conclusion: Use of Aviptadil was safe and effective in improving the
resolution of respiratory failure, shortening the time to recovery, decreasing respiratory distress and preventing
death in respiratory failure patients. The rapidity and magnitude of clinical effect suggests a highly specific role of
Aviptadil in combating the lethal effects of Acute Respiratory Distress Syndrome associated with COVID-19
Instead Something is up.... additional big cheese are exiting. Lots of speculation.
From HODL 6 hours ago ......Y board.
Resignation of Alessandra Daigneault as Chief Corporate Officer, General Counsel and Corporate Secretary
On May 19, 2022, Ms. Alessandra Daigneault tendered her resignation as Chief Corporate Officer, General Counsel and Corporate Secretary of NRx Pharmaceuticals, Inc. (the “Company”) effective on July 18, 2022 or such earlier date as may be agreed with the Company. Ms. Daigneault is leaving the Company to pursue other personal and professional interests.
The Company’s interim Chief Executive Officer, Mr. Robert Besthof, expressed his thanks to Ms. Daigneault for her outstanding contributions to the Company, including overseeing the merger of NeuroRx, Inc, and Big Rock Partners Acquisition Corp in May 2021, which resulted in the formation of the Company.
Mr. Michael Kunz, the Company’s Deputy General Counsel, is expected to assume the duties of General Counsel and Corporate Secretary.
Resignation of Mr. Ira Strassberg as Chief Financial Officer and Treasurer
On May 19, 2022, Mr. Ira Strassberg tendered his resignation as Chief Financial Officer and Treasurer of the Company effective July 18, 2022. Mr. Strassberg is leaving the Company to pursue other personal and professional interests. Mr. Strassberg will continue to fulfill his duties as Chief Financial Officer and Treasurer of the Company until his departure. The Board will be conducting a search for a successor.
The Chairman of the Company’s Audit Committee, Mr. Patrick Flynn, and Mr. Besthof, expressed their thanks to Mr. Strassberg for his meaningful contributions to the Company, including the establishment of robust internal controls and a strong finance and accounting function at the Company.
At this low low price, insiders sb buying millions of shares ...IF
there is a bright future for Neuro, imho. .
Why are the big insiders not buying in at low prices ???? Where is bowtie ???
FY...Interesting From Zaran....13 hours ago on the Y board.
The confluence of timing and events is rapidly approaching. Disgruntled former and current Dept. of Health and Human Resource employees are enumerating issues we each have learned about through our involvement here and in the public tackling of the Covid-19 pandemic.
On May 26th. the DSMB of the ACTIV 3b Clinical Trial monitoring the results of the Aviptadil vs.
Remdesivir vs. Placebo comparisons is going to meet to review all of the data from those trial participants who have completed 90 days post infusion to date. We are being told that they will also consider all other data available to them, including (my belief) the information / data packages included with the EUA and BTD, most recent filings. If the drug works as we believe, then, these board members will see "again," not only the safety of VIP in this IV version, but it's overwhelming efficacy compared to Remdesivir and placebo. Remembering that the April DSMB meeting was "delayed' so that precisely and specifically MORE data would be available for them to REVIEW! This is an extremely important meeting. As we were lead to believe earlier this year, the preponderance of trial participants for the Aviptadil portion had a higher percentage of patients so all the better for safety and efficacy readings at this critical juncture.
What do they do when they update their knowledge with these possible results? Good question needing to be placed in context to the above mentioned internal ongoing inquiry and to the external Congressional investigations which are becoming increasingly strident in "demanding" working therapeutics and now, preparation for subsequent (think, Fall) Seasons of Covid infections. Funding for the Covid Pandemic War is also concurrently in full swing in Congress. Results are being demanded by both republicans and democrats, and is in no small way a part of this funding process. Yes, even CongressPeople are investigating and becoming dis-satisfied in their analysis of results. Add to this mixture... Preparation of any new therapeutic by a small organization like our own and "now" collaborator NRXP, is as has been said by Dr. Harris in his most recent public conversation with Dr. Fauci, going to take a few months for initial production and dissemination under BARDA's stewartship to reach hospital ICU's across our country. The rest of the world not even considered, yet!
Throw in the fact that our trial is the only one left in ACTIV 3b for critically ill patients. Throw in that the newest EUA granted for Olumiant is only marginally better (2 or 3 percent) than it's comparison to Remdesivir not 4X better like our racehorse Aviptadil. Throw in that more recent studies have found that Remdesivir "does not work" for late stage covid. And, recommendations that it be moved to being an earlier stage therapeutic. Keep everybody happy, right?
Consider that on April 22nd. India issued an EUA for Aviptadil with a report of outstanding results on all measures. Consider that the Swiss Inhaler Trial has ended recruiting and results will be forthcoming as final results are tabulated. Are we the USA, the premier Medical Establishment, or what? Late to the Party?
And, perhaps more important than anything else is that 300 people here in the USA are dying needlessly everyday from respiratory complication of Covid-19. I say that just having gotten over the disease. Fortunately for me, it was mild, but for those who can't breathe, hello? what in god's name are we waiting for?
We've all been waiting and if lucky, we've learned patience and have a better understanding of how our government works and certainly how the medical establishment does it's thing. So, we are wiser and smarter for everything we have gone through. Don't get me wrong, no where did I say easy or fun, it's been hard I'm sure on all of us. But, there comes a time, an event is created by multiple interactions, a black swan event is just this very thing. Seemingly, disparate occurrences happening create. This is a time now when many related areas of importance to us shareholders and believers in this drug that are acting in synchronicity. Is there enough momentum to get us over the hump? If the results of the IV infusions in the ACTIV 3b trial are as anticipated, I think we get our EUA now. Trial stopped, immediate approval.
Why? It's getting awfully hot in Washington with the bickering and CongressPeople aren't stupid. They know about Big Pharma, too, and get compensated by lobbyists and in donations to their PAC's and campaigns. Nothing new here, but a rising tide of trust has been turned into a rising tide of dis-satisfaction and questions of betrayal and selling out. Bottom line, voters are people like you and me. All the things mentioned above.
Don't fail to see that the spring is wound very, very tight. If we were to get an EUA, this stock is going to explode. Market caps are as much extrapolations as data, expect lunacy.
Interesting From .........Wong yesterday on a Y board
Shout out to Greg Larssen with the DD.
$RLFTF, $NRXP - Relief Therapeutics
Gem found in an MSN article on the death of the BriLife vaccine :
"... the Health Ministry ... refused to offer regulatory support & eventually approval for the jab, leading to NRx withdrawal & Javitt stepping down."
https://t.co/HUwCxdO7Hi
https://www.msn.com/en-gb/health/medical/israels-covid-19-vaccine-brilife-is-dead/ar-AAXxw2N
Bombshell: Majority of Vaccinated People May Have Myocarditis
Dr. Robert Malone warns that heart inflammation may be widespread among the vaxxed
A week ago, the “Global Covid Summit” convened with luminaries like Dr. Robert Malone, Dr. Peter McCullough, and Dr. Ryan Cole leading the event. Over 17,000 scientists and doctors signed a joint statement that you simply must read.
https://emeralddb3.substack.com/p/bombshell-majority-of-vaccinated?s=r
Seems like a safe effective therapeutic like AVIPTADIL would be very helpful and something the FDA should leap ahead to approve .... the clot shots sure have some problems evidently eh ?
https://stevekirsch.substack.com/p/do-you-know-any-kids-18-and-younger?s=r
https://amgreatness.com/2022/05/17/dr-robert-malone-rotten-to-the-core-fda-knew-covid-vaccines-could-spur-viral-reactivation-but-said-nothing/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062939/
Who do we gotta pay for approval ???
Something is not right with the so called "vaccines"
https://citizenfreepress.com/column-2/walgreens-data-shows-the-vaccine-and-booster-arent-working/
https://twitter.com/backtolife_2022/status/1524397347630895104
https://citizenfreepress.com/breaking/when-you-lose-good-morning-america/
https://www.dailymail.co.uk/news/article-10812887/Baby-drowned-three-inches-bathwater-mother-fainted-day-taking-Covid-jab.html
https://citizenfreepress.com/breaking/the-scamdemic-will-never-be-over/
https://uncoverdc.com/2022/05/12/the-pfizer-clinical-trial-is-there-evidence-of-fraud/
https://citizenfreepress.com/breaking/vaccinated-cleveland-indians-suffer-covid-outbreak/
https://citizenfreepress.com/breaking/pfizer-vaccine-has-just-12-efficacy-in-children-study/
https://citizenfreepress.com/column-2/walgreens-data-shows-the-vaccine-and-booster-arent-working/
Would it be too much to ask that maybe the FDA should try using a safe effective therapeutic like ..................AVIPTADIL ?
New Low $1.17 today. / so far.
Waiting for the great dr jj to buy in really big before considering another purchase.
Where is the bottom ??
High Numbers of Covid go with areas of High "VAX" Rates
https://www.wsj.com/articles/covid-19-cases-hospitalizations-rise-in-new-england-and-puerto-rico-11652094004
Too many nations/cities/states with similar problems
Nrx is getting destroyed again today. on very low volume.
Will jj ever decide to buy at any price with his own jack ?
And Side Bets on how low this will go ?
Just a matter of time, IMHO, before this company does not exist as it is today, with perhaps a buyout at a much much lower price, considering all the legal liabilities. ,
Plenty of countries w/ HigH "VAX" rates and HigH Infections
https://www.thegatewaypundit.com/2022/02/vaccinated-country-earth-highest-number-covid-deaths-per-million-people-week/
Go Figure..
We need a safe effective therapeutic like RLF 100
It can be done by state in the USA even.
Go Figure if you are not brain dead from the Covid Clot Shots.
Real Data Showing Why We Need a Safe Effective Therapeutic
Like Aviptadil......RLF 100....or the Zyesami variation of it.
New UK government data shows the COVID vaccines kill more people than they save
https://stevekirsch.substack.com/p/uk-government-data-shows-nobody-should?s=r
Plenty of other data showing negative benefits also of so called VAX...
Military Data,
VAERS,
And data by country showing countries with highest % oc clot shots with
the highest infection rates of covid.
peg1, some other possibilities of people and places with a voice
might include the following. And thanks for your efforts.
https://rwmalonemd.substack.com/
https://americasfrontlinedoctors.org/news/
https://twitter.com/P_McCulloughMD/with_replies?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
GoodStick, Very Much Agreed. Hopefully, but unfortunately, its looking like without FDA approvals and without any meaningful assets ( none I am aware of ) and settlement of all the open lawsuits with various lawfirms and RLF, its difficult to make a case for owning this stock.
FWIW...NRX IS AT ANOTHER NEW LOW IN ITS STOCK PRICE PRICE TODAY OF $1.56
SEEMS LIKE THE BULLS WOULD BE BUYING NOW, EH ?
PW, and sadly, NRX owns almost nothing at this point, and any
judgements could be greater than the entire market cap of this miserable
company, and the assets of those that have made terrible NRX mgmt decisions
Another ugly day for NRX ........ on ugly low volume.
https://stockcharts.com/h-sc/ui?s=NRXP&p=D&yr=0&mn=4&dy=0&id=p56160925541
One dollar a share is a real possibility.
Any word on the seller of the 8 million shares ?
Or the buyer if there is one ?
new lows continue for NRXP and insiders are not buying...
go figure, is the last one out a rotten egg ?